Skip to content
Research Article Open access CC BY 4.0

In-vitro Susceptibility of Candida Pathogens Isolated From Clinical Specimens to Available Antifungal Agents in Nigeria

D. Olusoga Ogbolu, O. A. Terry Alli, O. S. Adewumi, A. S. Oluremi

International Journal of TROPICAL DISEASE & Health · pp. 80–86 · Published 2 Apr 2015

10.9734/IJTDH/2015/16116

Abstract

Aim: To characterize clinical isolates of Candida species from a tertiary hospital in South West Nigeria and also to determine their susceptibility to antifungal agents in order to guide in the course of empirical treatment of patients visiting hospitals in Nigeria. Study Design: This was a cross sectional study. Place and Duration of Study: Medical Microbiology and Parasitology Laboratory, LAUTECH Teaching Hospital, Osogbo, Nigeria. Study duration was Five (5) months. Methods: One hundred and twenty-four Candida species obtained from various body sites were identified and speciated using conventional and analytical profile index (API) for Candida and the susceptibility to 5 antifungal agents was determined using disc and macrodilution methods. Results: Highest number of Candida was obtained from urine, 44 (35.5%); followed by High Vaginal Swabs (HVS), 32 (25.8%) and blood, 20 (16.1%). Highest frequencies were obtained from C. Krusei and C. tropicalis, 32 (25.8%) each, followed by C. Albicans and C. pseudotropicalis, 24 (19.4%) each, and C. gulliermondii,12 (9.7%). Susceptibility to amphotericin B was the highest (74%),followed by itraconazole (52%) while least susceptibility was found in ketoconazole (19.0%).Strains of C. krusei and C. guilliermondii demonstrated 100% resistance to fluconazole and clotrimazole, respectively. MIC50 in most cases were greater than clinical break points and MIC90 values ranged between 16 and >64 µg/ml for all antifungal agents except amphotericin B, 0.5 to 1 μg/ml. Conclusion: Majority of Candida isolates are resistant to azole drugs. Amphotericin B is a reasonable alternative drug for empirical treatment of candidiasis since routine drug susceptibility testing Candida does not exist yet in any hospital in Nigeria.

Candida infection antifungal agents susceptibility Nigeria

References (23)

  1. 1 The Yeasts. A Taxonomic Study [DOI]
  2. 2 Secular Trend of Hospital‐Acquired Candidemia among Intensive Care Unit Patients in the United States during 1989–1999 [DOI]
  3. 3 Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program [DOI]
  4. 4 A large-scale North American study of fungal isolates from nails: The frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns [DOI]
  5. 5 The Epidemiology of Candidemia in Two United States Cities: Results of a Population-Based Active Surveillance [DOI]
  6. 6 Candida guilliermondii , an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program [DOI]
  7. 7 INFECTIOUS MORBIDITY IN CRITICALLY ILL PATIENTS WITH CANCER [DOI]
  8. 8 Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors [DOI]
  9. 9 Risk Factors and Predictors of Outcome in Patients with Cancer and Breakthrough Candidemia [DOI]
  10. 10 Fatal Disseminated Candidiasis Due to Amphotericin-B-Resistant Candida guilliermondii [DOI]
  11. 11 In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002–2003 [DOI]
  12. 12 Susceptibilities ofCandidaSpecies to Amphotericin B and Fluconazole: The Emergence of Fluconazole Resistance inCandida tropicalis [DOI]
  13. 13 NATIONAL NOSOCOMIAL INFECTIONS SURVEILLANCE SYSTEM H. SECULAR TREND OF HOSPITAL-ACQUIRED CANDIDEMIA AMONG INTENSIVE CARE UNIT PATIENTS IN THE UNITED STATES DURING 1989-1999
  14. 14 Epidemiology of Candida Bloodstream Infections in a Tertiary Care Institute in India [DOI]
  15. 15 Candida guilliermondii Fungemia in Patients with Hematologic Malignancies [DOI]
  16. 16 Comparison of Results of Voriconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program [DOI]
  17. 17 Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. results from a six-year study (1996–2001) [DOI]
  18. 18 Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients [DOI]
  19. 19 Case Report. Osteomyelitis caused by high resistant Candida guilliermondii [DOI]
  20. 20 In vitro antifungal sensitivity of fluconazole, clotrimazole and nystatin against vaginal candidiasis in females of childbearing age.
  21. 21 Disseminated Candida tropicalis in a Patient with Chronic Mucocutaneous Candidiasis [DOI]
  22. 22 Antifungal susceptibility testing of Candida spp. by relative growth measurement at single concentrations of antifungal agents [DOI]
  23. 23 Fluconazole in the treatment of oropharyngeal candidosis in HIV‐positive patients [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

10

Page views

0

PDF downloads

1

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.